Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented from first-in-human studies of two investigational menin inhibitors, SNDX-5613 and KO-539,...

Full description

Saved in:
Bibliographic Details
Published inJournal of hematology and oncology Vol. 16; no. 1; p. 17
Main Authors DiNardo, Katherine W, LeBlanc, Thomas W, Chen, Hui
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 03.03.2023
BioMed Central
BMC
Subjects
Acute myeloid leukemia
AML
Antibodies
Azacitidine
Biological products
Blood platelets
CD123 antigen
Clinical research
Conferences, meetings and seminars
Congresses as Topic
Correspondence
Hematology
Humans
Investigational therapies
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Medical research
Medicine, Experimental
Mutation
Oncology
Remission (Medicine)
Response rates
Tumor proteins
Viral antibodies
AML
Clinical research
Acute myeloid leukemia
Investigational therapies
Online AccessGet full text

Cover

More Information
Summary:Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented from first-in-human studies of two investigational menin inhibitors, SNDX-5613 and KO-539, in relapsed and refractory (R/R) acute myeloid leukemia (AML) with KMT2A rearrangement or mutant NPM1, with overall response rates (ORR) of 53% (32/60) and 40% (8/20), respectively. The addition of the novel drug pivekimab sunirine, a first-in-class antibody-drug conjugate targeting CD123, to azacitidine and venetoclax in R/R AML resulted in an ORR of 45% (41/91), which rose to 53% in those who were venetoclax naïve. Additional novel triplet treatment combinations included the addition of magrolimab, an anti-CD47 antibody, to azacitidine and venetoclax, with an ORR of 81% (35/43) in newly diagnosed AML, including an ORR of 74% (20/27) in TP53 mutated AML. The addition of the FLT3 inhibitor gilteritinib to azacitidine/venetoclax was also featured, with an ORR of 100% (27/27) in newly diagnosed AML and an ORR of 70% (14/20) in R/R AML.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-023-01411-x